A higher proportion of patients with previous TNF antagonist failure given vedolizumab also had a CDAI-100 response ( 100-point decrease in CDAI score from baseline ) at week 6 than those given placebo ( 39.2 % vs 22.3 % ; nominal P = .001 ; relative risk , 1.8 ; 95 % confidence interval , 1.2-2 .5 ) .